The U.S. Centers for Disease Control and Prevention has accepted its advisory panel's recommendations on vaccines for ...

The U.S. Centers for Disease Control and Prevention accepted its advisory panel's recommendations on vaccines for chikungunya ...

The CDC began recommending Ixchiq last year for adults traveling to countries where chikungunya is common. The vaccine uses a ...

The FDA and CDC are recommending a pause on the use of Ixchiq (chikungunya vaccine, live) in patients 60 years and older during an ongoing safety investigation.

The decision follows ongoing investigations into serious adverse events primarily reported in elderly individuals who ...

On the heels of similar moves in France and the European Union, U.S. health authorities are calling for a pause in the use of ...

The recommendations were approved on May 13, 2025, and are now the official recommendations of the CDC. The final recommendations ... Valneva make vaccines for chikungunya.

The FDA and CDC recommended a pause in administering Ixchiq, a chikungunya vaccine, in adults ages 60 and above after 17 serious adverse events, including two deaths.  About 80,000 Ixchiq doses have ...